Literature DB >> 23773641

The clinical and laboratory characteristics of Sjögren's syndrome that progresses to systemic lupus erythematosus: a retrospective case-control study.

Yunjiao Yang1, Zhengfu Li, Li Wang, Fengchun Zhang.   

Abstract

OBJECTIVE: We investigated the clinical and laboratory characteristics of Sjögren's syndrome-onset systemic lupus erythematosus (SS/SLE), focusing on the possible risk factors of SS that allow development to SLE.
METHODS: The experimental group included 55 SS/SLE patients, and the control group included 55 primary SS (pSS) patients recruited from our department between 1997 and 2012.
RESULTS: Compared with the control group, SS/SLE patients showed a younger age of onset of SS (31 ± 12 vs. 39 ± 11 years, P = 0.001). In clinical characteristics, SS/SLE patients showed a lower frequency of xerostomia (78.2% vs. 96.4%, P = 0.016) and interstitial lung disease (27.3% vs. 54.5%, P = 0.004), and a higher frequency of arthritis (74.5% vs. 40.0%, P = 0.000). In laboratory characteristics, SS/SLE patients showed a higher frequency of leukopenia (56.4% vs. 29.1%, P = 0.004), proteinuria (27.3% vs. 7.3%, P = 0.009), and low complement levels (CH50 : 30.9% vs. 1.8%; C3 : 54.5% vs. 12.7%; C4: 41.8% vs. 7.3%, P = 0.000). The multivariate analysis using logistic regression revealed that age of onset, low levels of C3 and C4 were the independent risk factors of SS/SLE (age of onset: RR = 0.919, P = 0.000; low C3 levels: RR = 9.659, P = 0.000; low C4 levels: RR = 6.035, P = 0.007).
CONCLUSION: The SS/SLE patients had an earlier age of onset, higher incidences of arthritis, leucopenia, proteinuria and low complement levels, and lower incidences of xerostomia and interstitial lung disease compared with pSS patients. These results suggest that we should be vigilant with the pSS patients who have all these mentioned clinical and laboratory characteristics, and are more likely to develop SS/SLE.
© 2013 The Authors International Journal of Rheumatic Diseases © 2013 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23773641     DOI: 10.1111/1756-185X.12088

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  5 in total

1.  Sjögren's syndrome associated with systemic lupus erythematosus.

Authors:  Mehmet Taşdemir; Chiar Hasan; Ayşe Ağbaş; Özgür Kasapçopur; Nur Canpolat; Lale Sever; Salim Çalışkan
Journal:  Turk Pediatri Ars       Date:  2016-09-01

Review 2.  Primary Sjögren's syndrome with diffuse cystic lung changes developed systemic lupus erythematosus: a case report and literature review.

Authors:  Xiao Liu; Hao Li; Yunhong Yin; Dedong Ma; Yiqing Qu
Journal:  Oncotarget       Date:  2017-05-23

3.  Hypocomplementemia in primary Sjogren's syndrome: association with serological, clinical features, and outcome.

Authors:  Wei Lin; Zhifei Xin; Jialan Wang; Xiuying Ren; Yixuan Liu; Liu Yang; Shaoying Guo; Yupeng Yang; Yang Li; Jingjing Cao; Xiaoran Ning; Meilu Liu; Yashuang Su; Lijun Sun; Fengxiao Zhang; Wen Zhang
Journal:  Clin Rheumatol       Date:  2022-03-29       Impact factor: 3.650

4.  Clinical Profile and Significance of Mucocutaneous Lesions of Primary Sjögren's Syndrome: A Large Cross-sectional Study with 874 Patients.

Authors:  Lei Xuan; Yi-Dong Zhang; Li Li; Yue-Ping Zeng; Hao-Ze Zhang; Jing Wang; Zhen-Hua Dong
Journal:  Chin Med J (Engl)       Date:  2017-10-20       Impact factor: 2.628

5.  Patients with early-onset primary Sjögren's syndrome have distinctive clinical manifestations and circulating lymphocyte profiles.

Authors:  Lin Wei; Xin Zhifei; Ning Xiaoran; Liu Meilu; Li Yang; Liu Yixuan; Ren Xiuying; Su Yashuang; Cao Jingjing; Guo Shaoying; Yang Liu; Sun Lijun; Zhang Fengxiao; Zhang Wen
Journal:  Rheumatology (Oxford)       Date:  2022-02-02       Impact factor: 7.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.